Astria Therapeutics (NASDAQ:ATXS) Price Target Raised to $28.00 at Oppenheimer

Astria Therapeutics (NASDAQ:ATXS) had its price target upped by analysts at Oppenheimer from $26.00 to $28.00 in a report released on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the biotechnology company’s stock. Oppenheimer’s price target would indicate a potential upside of 163.90% from the company’s previous close.

A number of other equities analysts also recently commented on ATXS. HC Wainwright restated a “buy” rating and set a $16.00 target price on shares of Astria Therapeutics in a report on Friday, September 27th. Wedbush reaffirmed an “outperform” rating and issued a $22.00 target price on shares of Astria Therapeutics in a research report on Tuesday, August 13th. TD Cowen assumed coverage on shares of Astria Therapeutics in a research report on Monday, July 29th. They set a “buy” rating and a $35.00 price target on the stock. Finally, Evercore ISI upgraded shares of Astria Therapeutics to a “strong-buy” rating in a report on Wednesday, August 14th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Buy” and an average price target of $25.60.

Astria Therapeutics Trading Down 4.9 %

Shares of NASDAQ:ATXS opened at $10.61 on Thursday. The company has a 50-day moving average price of $11.46 and a 200-day moving average price of $10.61. The company has a market cap of $598.67 million, a price-to-earnings ratio of -4.61 and a beta of 0.71. Astria Therapeutics has a 12 month low of $4.26 and a 12 month high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last announced its quarterly earnings results on Monday, August 12th. The biotechnology company reported ($0.43) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.05). As a group, research analysts forecast that Astria Therapeutics will post -1.68 EPS for the current fiscal year.

Institutional Trading of Astria Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in ATXS. Quest Partners LLC boosted its holdings in Astria Therapeutics by 3,310.6% in the second quarter. Quest Partners LLC now owns 3,206 shares of the biotechnology company’s stock worth $29,000 after acquiring an additional 3,112 shares in the last quarter. Ameritas Investment Partners Inc. raised its position in shares of Astria Therapeutics by 135.6% in the 1st quarter. Ameritas Investment Partners Inc. now owns 4,971 shares of the biotechnology company’s stock worth $70,000 after purchasing an additional 2,861 shares during the last quarter. SG Americas Securities LLC bought a new position in Astria Therapeutics in the 3rd quarter worth about $155,000. Hsbc Holdings PLC purchased a new stake in Astria Therapeutics during the 2nd quarter valued at about $171,000. Finally, Price T Rowe Associates Inc. MD bought a new stake in Astria Therapeutics during the 1st quarter valued at about $200,000. Hedge funds and other institutional investors own 98.98% of the company’s stock.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.